Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Revenue projections:

Revenue projections for TORNTPHARM
Revenue projections for TORNTPHARM

Torrent Pharmaceuticals Limited is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.126000
forwardPE 47.659393
debtToEquity 85.446000
earningsGrowth -0.217000
revenueGrowth 0.418000
grossMargins 0.757640
operatingMargins 0.201960
trailingEps 63.960000
forwardEps 94.759920

TORNTPHARM's current ratio of 1.126 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring TORNTPHARM is unlikely to face difficulties in meeting immediate financial obligations.
TORNTPHARM's high debt-to-equity ratio indicates significant leverage, meaning the company has more debt compared to its equity. While this can accelerate growth, it also increases financial risk if revenue or profits decline.
Positive gross and operating margins for TORNTPHARM suggest that the company is operating profitably. These margins highlight TORNTPHARM's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
With a forward EPS greater than its trailing EPS, TORNTPHARM is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for TORNTPHARM
Price projections for TORNTPHARM

TORNTPHARM's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Insider Transactions:

Insider Transactions for TORNTPHARM
Insider Transactions for TORNTPHARM


TORNTPHARM saw 1 transactions to buy shares, with a market price of 3939.0.There were no buy transactions during the given timeframe.The ongoing selling activity at Torrent Pharmaceuticals Limited's current price levels suggests a potential risk of further declines. If more investors continue to sell, this trend could lead to continued downward pressure on the stock's price.

Recommendation changes over time:

Recommendations trend for TORNTPHARM
Recommendations trend for TORNTPHARM


TORNTPHARM has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see TORNTPHARM as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.